Skip to content

Calculus partially Exits Scancell

Calculus Capital has successfully exited its investors’ shares in Scancell – a biotech company which develops novel immunotherapies for the treatment of cancer, based upon its ImmunoBody® and Moditope® technology platforms. Calculus sold the shares in Scancell through a placing in the market, delivering yet another great return to our investors. Fund 8: In price per share: … Continued